Piperacillin-tazobactam in the treatment of severe intra-abdominal and urinary tract infections in the Russian Federation | CMAC

Piperacillin-tazobactam in the treatment of severe intra-abdominal and urinary tract infections in the Russian Federation

Clinical Microbiology and Antimicrobial Chemotherapy. 2024; 26(2):171-187

​ Andreeva I.V., Stetsiouk O.U., Andreev V.A., Kozlov R.S.
10.36488/cmac.2024.2.171-187
piperacillin-tazobactam β-lactam antibiotics urinary tract infections intraabdominal infections antibacterial therapy antimicrobials
Section
Antimicrobials
Type
Review
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2024; 26(2):171-187

Abstract

Piperacillin/tazobactam is a well-known β-lactam antibiotic that has been used in clinical practice since 1993. The review presents the clinical and pharmacological characteristics of piperacillin-tazobactam, the results of clinical studies and determines place of this antibiotic in the treatment of patients with severe urinary tract infections and intraabdominal infections in the light of current data of pathogens’ susceptibility in the Russian Federation and current clinical guidelines.

Irina V. Andreeva

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

Olga U. Stetsiouk

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

Andreev V.A.

Smolensk State Medical University, Smolensk, Russia

Roman S. Kozlov

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

  • 1. Stetsiouk O.U., Andreeva I.V. Modern principles of antibacterial therapy of severe and life-threatening bacterial infections. Farmateka. 2008;(4):12-17. Russian.
  • 2. Kozlov R.S., Stetsiouk O.U., Andreeva I.V. Current trends in antibiotic resistance of nosocomial infection pathogens in the Russian ICU: what's coming next? Intensivnaja terapija. 2007;4:217-227. Russian.
  • 3. Glazanova T.V., Shilova E.R. Immune system disturbances after a new coronavirus infection COVID-19. Zhurnal infektologii. 2022;14(4):26-37. Russian. DOI: 10.22625/2072-6732-2022-14-4-26-37
  • 4. Khachatryan N.N., Fesenko Т.А., Vabischevitch N.К., Ohinko L.V., Muslimov B.G., Tchupalov М.О. Current view on antimicrobial therapy of intra-abdominal infections. Kliniceskaa mikrobiologia i antimikrobnaa himioterapia. 2013;15(4):301-308. Russian.
  • 5. Handbook of antimicrobial therapy. Issue 3. Edited by Kozlov R.S., Dekhnich A.V. Smolensk: IACMAC, 2013, 480 p. Russian.
  • 6. Stetsiouk O.U., Kovalenko T.N., Andreeva I.V., Belkova Yu.A. The known-unknown: third- and fourthgeneration cephalosporins combined with sulbactam. Kliniceskaa mikrobiologia i antimikrobnaa himioterapia. 2023;25(1):41-55. Russian. DOI: 10.36488/cmac.2023.1.41-55
  • 7. Zakharenkov I.A., Rachina S.A., Kozlov R.S., Belkova Yu.A. Consumption of systemic antibiotics in the Russian Federation in 2017-2021. Kliniceskaa mikrobiologia i antimikrobnaa himioterapia. 2022;24(3):220-225. Russian. DOI: 10.36488/cmac.2022.3.220-225
  • 8. Klein E.Y., Milkowska-Shibata M., Tseng K.K., Sharland M., Gandra S., Pulcini C., et al. Assessment of WHO antibiotic consumption and access targets in 76 countries, 2000-15: an analysis of pharmaceutical sales data. Lancet Infect Dis. 2021;21(1):107-115. DOI: 10.1016/S14733099(20)30332-7
  • 9. Gomon Yu.M., Kolbin A.S., Arepyeva M.A., Kalyapin A.A., Balykina Yu.E., Kurylev A.A., et.al. Antimicrobial drug consumption in the Russian Federation (2008-2022): pharmacoepidemiological study. Kliniceskaa mikrobiologia i antimikrobnaa himioterapia. 2023;25(4):395-400. Russian. DOI: 10.36488/cmac.2023.4.395-400
  • 10. Ageevets V.A., Sulian O.S., Avdeeva A.A., Chulkova P.S., Gostev V.V., Ageevets I.V., et al. Comparative activity of carbapenem antibiotics against gram-negative carbapenemase producers of different groups. Antibiotiki i himioterapija. 2022;67(1-2):9-15. Russian. DOI: 10.37489/0235-2990-2022-67-1-2-9-15
  • 11. Perry C.M., Markham A. Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections. Drugs. 1999;57(5):805-843. DOI: 10.2165/00003495-199957050-00017
  • 12. Reshedko G.K. Microbiologic and clinical aspects of piperacillin/tazobactam use. Kliniceskaa mikrobiologia i antimikrobnaa himioterapia. 2009;11(3):239-252. Russian.
  • 13. Gomon Yu.M. Piperacillin-tazobactam: prospects for use in real-world practice. Real-world data and evidence. 2023;3(3):1-7. Russian. DOI: 10.37489/2782-3784-myrwd-36
  • 14. Kozlov S.N., Kozlov R.S. Modern antimicrobial chemotherapy. Manual for physicians. Moscow: LLC "Medical Information Agency", 2017. 400 p. Russian.
  • 15. Gin A., Dilay L., Karlowsky J.A., Walkty A., Rubinstein E., Zhanel G.G. Piperacillin-tazobactam: a beta-lactam/betalactamase inhibitor combination. Expert Rev Anti Infect Ther. 2007;5(3):365-383. DOI: 10.1586/14787210.5.3.365
  • 16. Beloborodov V.B., Goloschapov O.V., Gusarov V.G., Dekhnich А.V., Zamyatin M.N., Zubareva N.A., et al. Guidelines of the Association of AnesthesiologistsIntensivists, the Interregional Non-Governmental Organization Alliance of Clinical Chemotherapists and Microbiologists, the Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy (IACMAC), and NGO Russian Sepsis Forum "Diagnostics and antimicrobial therapy of the infections caused by multiresistant microorganisms" (update 2022). Messenger of anesthesiology and resuscitation. 2022;9(2):84-114. Russian. DOI: 10.21292/2078-5658-202219-2-84-114
  • 17. Sörgel F., Kinzig M. Pharmacokinetics and tissue penetration of piperacillin/tazobactam with particular reference to its potential in abdominal and soft tissue infections. Eur J Surg Suppl. 1994;(573):39-44. PMID: 7524794.
  • 18. Portal of general information resources and open data. General characteristics of the drug Razobactam. Available at: https://portal.eaeunion.org/sites/commonprocesses/ru-ru/Pages/CardView.aspx?documentId=664f237930dcf8d822c136b3&codeId=P.MM.01. Accessed September 24, 2024. Russian.
  • 19. Naber K.G., Savov O., Salmen H.C. Piperacillin 2 g/tazobactam 0.5 g is as effective as imipenem 0.5 g/cilastatin 0.5 g for the treatment of acute uncomplicated pyelonephritis and complicated urinary tract infections. Int J Antimicrob Agents. 2002;19(2):95103. DOI: 10.1016/s0924-8579(01)00481-2
  • 20. Zhiyong Z., Xiaoju L., Yanbin L., Yao Y., Rujia Y., Xueqin F., et al. Piperacillin-sulbactam versus piperacillin-tazobactam: a multicentre, randomised, single-blind, controlled clinical trial. Int J Antimicrob Agents. 2005;26(1):22-27. DOI: 10.1016/j.ijantimicag.2005.02.018
  • 21. Seo Y.B., Lee J., Kim Y.K., Lee S.S., Lee J.A., Kim H.Y., et al. Randomized controlled trial of piperacillintazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum betalactamase-producing Escherichia coli. BMC Infect Dis. 2017;17(1):404. DOI: 10.1186/s12879-017-2502-x
  • 22. Kaye K.S., Rice L.B., Dane A.L., Stus V., Sagan O., Fedosiuk E., et al. Fosfomycin for injection (ZTI-01) versus piperacillin-tazobactam for the treatment of complicated urinary tract infection including acute pyelonephritis: ZEUS, a phase 2/3 randomized trial. Clin Infect Dis. 2019;69(12):2045-2056. DOI: 10.1093/cid/ciz181
  • 23. Kaye K.S., Belley A., Barth P., Lahlou O., Knechtle P., Motta P., et al. Effect of Cefepime/enmetazobactam vs piperacillin/tazobactam on clinical cure and microbiological eradication in patients with complicated urinary tract infection or acute pyelonephritis: a randomized clinical trial. JAMA. 2022;328(13):1304-1314. DOI: 10.1001/jama.2022.17034
  • 24. Sharara S.L., Amoah J., Pana Z.D., Simner P.J., Cosgrove S.E., Tamma P.D. Is piperacillin-tazobactam effective for the treatment of pyelonephritis caused by extendedspectrum β-lactamase-producing organisms? Clin Infect Dis. 2020;71(8):e331-e337. DOI: 10.1093/cid/ciz1205
  • 25. Kulabukhov V.V., Shabanov А.К., Andreeva I.V., Stetsiouk О.U., Andreev V.А. Biomarkers of infection in the optimization of antibacterial therapy: justified expectations. Kliniceskaa mikrobiologia i antimikrobnaa himioterapia. 2020;22(3):175-188. Russian. DOI: 10.36488/cmac.2020.3.175-187
  • 26. Palagin I.S., Sukhorukova M.V., Dekhnich A.V., Edelstein M.V., Shevelev A.N., Grinyov A.V., et al. Current state of antibiotic resistance of pathogens causing community-acquired urinary tract infections in Russia: «DARMIS» study (2010-2011). Kliniceskaa mikrobiologia i antimikrobnaa himioterapia. 2012;14(4):280-302. Russian.
  • 27. Palagin I.S., Sukhorukova M.V., Dekhnich A.V., Edelstein M.V., Perepanova T.S., Kozlov R.S. and “DARMIS-2018” Study Group. Antimicrobial resistance of pathogens causing community-acquired urinary tract infections in Russia: results of multicenter study “DARMIS-2018”. Kliniceskaa mikrobiologia i antimikrobnaa himioterapia. 2019;21(2):134-146. Russian. DOI: 10.36488/cmac.2019.2.134-146
  • 28. Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy (IACMAC). Report of research «Antimicrobial resistance of pathogens causing community-acquired urinary tract infections in Russia: results of multicenter study DARMIS-2023», Smolensk, 2023 г. Russian.
  • 29. Bonkat G., Bartoletti R., Bruyère F., Cai T., Geerlings S.E., Köves B., et al. EAU Guidelines on Urological Infections. Edn. presented at the EAU Annual Congress Amsterdam, the Netherlands 2022. ISBN 978-94-92671-16-5.
  • 30. Perepanova T.S., Kozlov R.S., Rudnov V.A., Sinyakova L.A., Palagin I.S. Antimicrobial therapy and prevention of infections of the kidneys, urinary tract and male genital organs. Federal clinical recommendations. Moscow: Uromedia, 2022. Russian.
  • 31. Baranov A.A., Kozlov R.S., Namazova-Baranova L.S., Andreeva I.V., Vishneva E.A., Zokirov N.Z., et al. Urinary tract infection in children. Clinical Guidelines (ID 281), 2021, 51 p. Available at: https://cr.minzdrav.gov.ru/recomend/281_2. Accessed September 24, 2024. Russian.
  • 32. Sartelli M., Coccolini F., Kluger Y., Agastra E., AbuZidan F.M., Abbas A.E.S., et al. WSES/GAIS/SIS-E/WSIS/AAST global clinical pathways for patients with intra-abdominal infections. World J Emerg Surg. 2021;16(1):49. DOI: 10.1186/s13017-021-00387-8
  • 33. Sartelli M., Barie P., Agnoletti V., Al-Hasan M.N., Ansaloni L., Biffl W., et al. Intra-abdominal infections survival guide: a position statement by the Global Alliance For Infections In Surgery. World J Emerg Surg. 2024;19(1):22. DOI: 10.1186/s13017-024-00552-9
  • 34. Beketov A.S., Sidorenko S.V., Pisarev V.V., Komarov R.M. Clinical and economic evaluation of antibacterial therapy of intra-abdominal infections. Good clinical practice. 2002;(3):60-67. Russian.
  • 35. Hackel M.A., Badal R.E., Bouchillon S.K., Biedenbach D.J., Hoban D.J. Resistance rates of intra-abdominal isolates from intensive care units and non-intensive care units in the United States: the study for monitoring antimicrobial resistance trends 2010-2012. Surg Infect (Larchmt). 2015;16(3):298-304. DOI: 10.1089/sur.2014.060
  • 36. Kozlov R.S., Golub A.V., Dekhnich A.V., Sukhorukova M.V., SMART Study Group. Antimicrobial resistance of gramnegative microorganisms causing complicated intraabdominal infections in Russia. Kliniceskaa mikrobiologia i antimikrobnaa himioterapia. 2015;17(3):227-234. Russian.
  • 37. Kuzmenkov A.Yu., Vinogradova A.G., Trushin I.V., Edelstein M.V., Avramenko A.A., Dekhnich A.V., et al. AMRmap – antibiotic resistance surveillance system in Russia. Kliniceskaa mikrobiologia i antimikrobnaa himioterapia. 2021;23(2):198-204. Russian. DOI: 10.36488/cmac.2021.2.198-204
  • 38. Global Alliance for Infections in Surgery Working Group. A global declaration on appropriate use of antimicrobial agents across the surgical pathway. Surg Infect (Larchmt). 2017;18(8):846-853. DOI: 10.1089/sur.2017.219
  • 39. Sartelli M., Weber D.G., Ruppé E., Bassetti M., Wright B.J., Ansaloni L., et al. Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA). World J Emerg Surg. 2016;11(1):33. DOI: 10.1186/s13017-016-0089-y
  • 40. Mazuski J.E., Tessier J.M., May A.K., Sawyer R.G., Nadler E.P., Rosengart M.R., et al. The Surgical Infection Society revised guidelines on the management of intraabdominal infection. Surg Infect (Larchmt). 2017;18(1):176. DOI: 10.1089/sur.2016.261
  • 41. Sartelli M., Chichom-Mefire A., Labricciosa F.M., Hardcastle T., Abu-Zidan F.M., Adesunkanmi A.K., et al. The management of intra-abdominal infections from a global perspective: 2017 WSES guidelines for management of intra-abdominal infections. World J Emerg Surg. 2017;12:29. DOI: 10.1186/s13017-017-0141-6
  • 42. Montravers P., Dupont H., Leone M., Constantin J.M., Mertes P.M., Société française d’anesthésie et de réanimation (Sfar), et al. Guidelines for management of intra-abdominal infections. Anaesth Crit Care Pain Med. 2015;34(2):117130. DOI: 10.1016/j.accpm.2015.03.005
  • 43. Stanford Antimicrobial Safety and Sustainability Program. Stanford Health Care Intra-Abdominal Infections Empiric Antibiotics Guidance. Available at: https://med.stanford.edu/content/dam/sm/bugsanddrugs/documents/clinicalpathways/SHC-Intra-abdominal-Guidelines.pdf. Accessed September 24, 2024.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared